INVO FERTILITY INC (IVF)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$0.98+0.16%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
Research Workspace
Put IVF beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care Equipment: fringe margins under pressure (3q confirmed)
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar broken — Sustain revenue growth through acquisitions and organic expansion: FY26 revenue guidance $4.2M vs $10.4M target.
View ThesisRevenue is growing steadily — about 14% over the past year.
View GrowthManagement screens weak on capital allocation, margins.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is highly volatile — it swings about 3% on a typical day and fell roughly 98% in its worst 12-month stretch.
View RiskIVF must sustain revenue growth through acquisitions and organic expansion to justify its price. Recent financial performance has weakened, moving from the robust to the fragile. Revenue guidance for FY26 is $4.2M, below the $10.4M target. The stock trades at 0.3× price-to-sales, while the peer median is 2.9×. This shows the price reflects less growth than expected. The next-quarter miss probability is 64%, indicating elevated risk. Peer multiples imply a price about 88% above where it trades. This read is provisional.
Trailing returns as of 2026-09-04. IVF is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 1 analyst currently covering IVF (as of May 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare IVF with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| IVF Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 1 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Equipment — fair value, gap to price, and forward P/E.
Compare the value case
Put IVF next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Drive organic growth and pursue disciplined acquisitions
Revenue surge supports organic growth objective.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-04. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Advances: Improve operating income and Adjusted EBITDA
Q2 revenue growth indicates improved operating income.
Threatens: Improve operating income and Adjusted EBITDA
Earnings beat but revenue shortfalls impact operating income.
Threatens: Address regulatory compliance issues
Delisting notice raises regulatory compliance concerns.